Solventum (FRA:KB7) Other Long Term Assets: €784 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KB7 Solventum Corp FRA:KB7
28 GF Score
Price €73.40
! 7 Warning Signs
View Full Analysis

What is Solventum Other Long Term Assets?

Solventum FRA:KB7 -0.54% 28 Other Long Term Assets is €784 Mil as of Jun. 2026. GuruFocus rates FRA:KB7 with a GF Score™ of 28/100. The stock has 7 warning signs investors should review.

Solventum's other long-term assets for the quarter that ended in Jun. 2026 was €784 Mil.

Solventum's quarterly other long-term assets increased from Dec. 2025 (€694 Mil) to Mar. 2026 (€734 Mil) and increased from Mar. 2026 (€734 Mil) to Jun. 2026 (€784 Mil).

Solventum's annual other long-term assets increased from Dec. 2023 (€486 Mil) to Dec. 2024 (€635 Mil) and increased from Dec. 2024 (€635 Mil) to Dec. 2025 (€694 Mil).

Solventum Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Solventum's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solventum Other Long Term Assets Chart

Solventum Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial 223.91 337.95 486.01 635.07 694.30

Solventum Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,581.06 636.44 694.30 733.52 783.80
FRA:KB7
28GF Score
Solventum Corp FRA:KB7
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solventum Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of €784 Mil mean?
Solventum (FRA:KB7) has a Other Long Term Assets of €784 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Solventum and its competitors.
Is Solventum's Other Long Term Assets too high?
Solventum's current Other Long Term Assets is €784 Mil. Overall, Solventum has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Solventum's Other Long Term Assets compare to COO and ALGN?
Solventum's Other Long Term Assets of €784 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Medical Devices & Instruments company?
A good Other Long Term Assets depends on the Medical Devices & Instruments industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Solventum and its competitors. Solventum's current Other Long Term Assets is €784 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solventum stock overvalued right now?
Solventum (FRA:KB7) has a current Other Long Term Assets of €784 Mil. The current Other Long Term Assets is €784 Mil. Solventum's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Solventum (FRA:KB7), the current Other Long Term Assets is €784 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solventum Business Description

Address 2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
28GF Score

Get the complete analysis for FRA:KB7

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€73.40
Price